Company profile
Versameb AG
Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNA molecules in multiple disease areas with high unmet medical need including immunological disorders, oncology and myology. For more information, please visit www.versameb.com.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
